Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Ying, J."" wg kryterium: Autor


Wyświetlanie 1-14 z 14
Tytuł :
Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study
Autorzy :
Peter G. Hendrickson
Yukun Luo
Wendy Kohlmann
Josh Schiffman
Luke Maese
Andrew J. Bishop
Shane Lloyd
Kristine E. Kokeny
Ying J. Hitchcock
Matthew M. Poppe
David K. Gaffney
Randa Tao
Pokaż więcej
Temat :
LFS
Li‐Fraumeni syndrome
p53
radiation
RT‐induced malignancy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Cancer Medicine, Vol 9, Iss 21, Pp 7954-7963 (2020)
Opis pliku :
electronic resource
Relacje :
https://doaj.org/toc/2045-7634
Dostęp URL :
https://doaj.org/article/82d90ab51709418495372fa6d2e6241b
Czasopismo naukowe
Tytuł :
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Autorzy :
Xu H; Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhang Q; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Liang L; Cancer Chemotherapy and Radiation Department, Peking University Third Hospital, Beijing, China.
Li J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Liu Z; Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China.
Li W; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yang G; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Xu F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Ying J; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhang S; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Wang Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2020 May; Vol. 9 (10), pp. 3328-3336. Date of Electronic Publication: 2020 Mar 13.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Autorzy :
Moser JC; HonorHealth Research Institute, Scottsdale, AZ, USA.
Chen D; Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Hu-Lieskovan S; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Grossmann KF; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Patel S; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Colonna SV; Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Ying J; Division of Public Health, Study Design and Biostatistics Center, Department of Family Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Hyngstrom JR; Surgical Oncology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2019 Dec; Vol. 8 (18), pp. 7637-7643. Date of Electronic Publication: 2019 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Melanoma/*drug therapy
Melanoma/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Aged ; Alleles ; Amino Acid Substitution ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Ipilimumab/administration & dosage ; Male ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Nivolumab/administration & dosage ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Proportional Hazards Models ; Protein Kinase Inhibitors/administration & dosage ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Autorzy :
Song P; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang F; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Y; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang G; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li W; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ying J; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gao S; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2019 Apr; Vol. 8 (4), pp. 1551-1557. Date of Electronic Publication: 2019 Mar 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Mutation*
Anaplastic Lymphoma Kinase/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Tumor Suppressor Protein p53/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib/administration & dosage ; Crizotinib/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Odds Ratio ; Oncogene Proteins, Fusion/genetics ; Prognosis ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma.
Autorzy :
Ying J; Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Wang Q; Department of Clinical Laboratory, Wenzhou People's Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, China.
Xu T; Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Lyu J; Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2018 Jun; Vol. 7 (6), pp. 2601-2611. Date of Electronic Publication: 2018 Apr 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*
Gene Expression Regulation, Neoplastic*
Models, Biological*
Endometrial Neoplasms/*genetics
Endometrial Neoplasms/*mortality
Adult ; Computational Biology/methods ; Endometrial Neoplasms/diagnosis ; Female ; Gene Expression Profiling ; Genome-Wide Association Study ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Prognosis ; Proportional Hazards Models ; ROC Curve ; Reproducibility of Results ; Transcriptome
Czasopismo naukowe
Tytuł :
A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia.
Autorzy :
Kaul S; University of Utah, Salt Lake City, Utah.
Korgenski EK; Intermountain Healthcare, Salt Lake City, Utah.
Ying J; University of Utah, Salt Lake City, Utah.
Ng CF; Tufts University School of Medicine, Boston, Massachusetts.
Smits-Seemann RR; University of Utah, Salt Lake City, Utah.
Nelson RE; University of Utah, Salt Lake City, Utah.
Andrews S; Primary Children's Hospital, Salt Lake City, Utah.
Raetz E; University of Utah, Salt Lake City, Utah.; Primary Children's Hospital, Salt Lake City, Utah.
Fluchel M; University of Utah, Salt Lake City, Utah.; Primary Children's Hospital, Salt Lake City, Utah.
Lemons R; University of Utah, Salt Lake City, Utah.; Primary Children's Hospital, Salt Lake City, Utah.
Kirchhoff AC; University of Utah, Salt Lake City, Utah.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2016 Feb; Vol. 5 (2), pp. 221-9. Date of Electronic Publication: 2015 Dec 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Health Care Costs*
Hospitalization/*economics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*epidemiology
Adolescent ; Adult ; Age Factors ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Outcome Assessment, Health Care ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Retrospective Studies ; Young Adult
Czasopismo naukowe
    Wyświetlanie 1-14 z 14

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies